OXNARD, Calif.--(company WIRE)--Jan 5, 2021--
remedy Pharmaceutical maintaining Corp. ("treatment" or the "enterprise") (OTC: CURR), a technology focused, vertically built-in drug delivery and product building business within the pharmaceutical and health & well being house, introduced today that the U.S. meals and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for its product CUREfilm Blue™, an oral soluble movie of sildenafil citrate (the lively ingredient latest in Viagra® 1 ) for the treatment of erectile dysfunction (ED). remedy is looking for approval of this product by the use of the 505(b)(2) regulatory pathway to expedite the U.S. approval technique.
CUREfilm Blue™ utilizes the business's patented and proprietary quick-dissolving drug beginning platform, referred to as CUREfilm™, to bring the energetic pharmaceutical ingredient (API) sildenafil citrate. through innovating past the ordinary pharmaceutical start of tablets and solutions, cure is advancing this uniquely discrete, handy and transportable oral film product for achieving a much better affected person event.
"seeing that cure became centered, relocating our flagship expertise CUREfilm™ through the FDA regulatory system has been at the cornerstone of our pharmaceutical approach. This approval of the IND submitting from the FDA marks a big milestone for our business, validating the cost-proposition of our expertise and proprietary dosage kind," talked about treatment CEO Rob Davidson. "Our oral film expertise makes complete sense to meet patients' sildenafil needs for treating ED. Our crew has labored diligently for the previous year to make several inroads on clinical efforts to achieve this vital accomplishment and i am assured that we are optimally placed to continue to trials in early 2021."
"The erectile dysfunction market has advanced significantly over the remaining a couple of years with the introduction of telemedicine. Our patent pending CUREfilm Blue™ oral soluble movie of sildenafil citrate should carry a major value proposition to patients, physicians and providers in the erectile dysfunction market," referred to treatment Chief business Officer, Jonathan Berlent.
The world erectile dysfunction drug market is projected to attain about USD$6.6 Billion by means of 2025, at a CAGR of 6.0% over the 5-year forecasted duration with sildenafil representing a majority of the market in accordance with a record by QYR analysis.
About remedy Pharmaceutical maintaining Corp.
treatment Pharmaceutical ® is the pioneering developer of CUREform™, a patented drug beginning platform that presents a couple of entertaining instant- and controlled-free up drug birth automobiles designed to enhance drug efficacy, safeguard, and affected person journey for a wide range of lively parts.
As a vertically built-in enterprise, treatment's 25,000 rectangular foot, FDA-registered, NSF ® and cGMP-certified manufacturing facility makes it possible for it to partner with pharmaceutical and wellbeing groups international for private and white-labeled production. remedy has partnerships within the U.S., China, Mexico, Canada, Israel, and other markets in Europe.
1 Viagra ® is a registered trademark of Pfizer Inc.
forward looking observation
Statements cure makes in this press release may consist of statements which are not ancient records and are regarded ahead-searching inside the which means of area 27A of the Securities Act of 1933, as amended ("Securities Act"), and part 21E of the Securities exchange Act of 1934, as amended ("change Act"), which can be constantly identified by way of phrases equivalent to "anticipates," "believes," "estimates," "expects," "intends," "may additionally," "plans," "projects," "seeks," "should," "will," and diversifications of such phrases or similar expressions. treatment intends these forward-searching statements to be covered by means of the safe harbor provisions for ahead-looking statements contained in part 27A of the Securities Act and section 21E of the exchange Act and is making this observation for purposes of complying with those safe harbor provisions. These forward-looking statements include, devoid of predicament, the skill to successfully market the partnered products, the problem in predicting the timing or outcomes of linked analysis and construction efforts, partnered product features and indications, advertising approvals and launches of other items, the influence of pharmaceutical trade law, the affect of competitive items and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held via competitors and other third events and the ability to attain financing on favorable terms. The forward-searching statements during this press liberate mirror cure's judgment as of the date of this press unencumber. cure disclaims any intent or duty to update these forward-looking statements. This press free up shall not constitute a suggestion to sell or the solicitation of a proposal to buy nor shall there be any sale of our securities in any state or jurisdiction through which such offer, solicitation or sale can be illegal just before registration or qualification beneath the securities legal guidelines of this kind of state or jurisdiction.
View source version on businesswire.com:https://www.businesswire.com/news/domestic/20210105005370/en/
CONTACT: Licensing Contact:
Jonathan Berlent
Chief company Officer
treatment Pharmaceutical
Jberlent@curepharma.com
516.660.9148
investment Contact:
Gary Zwetchkenbaum
Plum Tree Consulting LLC
gzplumtree@gmail.com
516.455.7662
Media Contact:
Kathryn Brown
CMW Media
treatment@cmwmedia.com
858.264.6600
key phrase: CALIFORNIA u.s. NORTH the usa
trade keyword: BIOTECHNOLOGY FDA PHARMACEUTICAL health
source: cure Pharmaceutical maintaining Corp.
Copyright enterprise Wire 2021.
PUB: 01/05/2021 08:00 AM/DISC: 01/05/2021 08:01 AM
http://www.businesswire.com/news/domestic/20210105005370/en
0 Comments